🏅 FDA Orphan Designation
Rilutek
Riluzole
Manufacturer: Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Indicated for:
FDA-Approved Indications (1)
Amyotrophic lateral sclerosisOrphan Designation
Treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and time to tracheostomy. First drug approved for ALS (1995).
Indications & Usage
Treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.
💙 Support Programs
View all →Rilutek
Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Riluzole
Sanofi
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.